Abeona Therapeutics (ABEO) Upgraded to “Buy” at BidaskClub

BidaskClub upgraded shares of Abeona Therapeutics (NASDAQ:ABEO) from a hold rating to a buy rating in a report released on Monday.

Several other brokerages also recently issued reports on ABEO. HC Wainwright reissued a buy rating and set a $30.00 price objective on shares of Abeona Therapeutics in a research report on Friday, April 20th. Cantor Fitzgerald reissued a buy rating and set a $36.00 price objective on shares of Abeona Therapeutics in a research report on Wednesday, May 16th. SunTrust Banks lowered their price objective on shares of Abeona Therapeutics to $23.00 and set a positive rating on the stock in a research report on Wednesday, May 16th. Maxim Group set a $35.00 price objective on shares of Abeona Therapeutics and gave the stock a buy rating in a research report on Monday, May 14th. Finally, ValuEngine raised shares of Abeona Therapeutics from a hold rating to a buy rating in a research report on Friday, June 1st. One analyst has rated the stock with a hold rating and ten have given a buy rating to the company. Abeona Therapeutics currently has an average rating of Buy and an average target price of $28.56.

Shares of Abeona Therapeutics stock opened at $15.90 on Monday. Abeona Therapeutics has a 1 year low of $4.70 and a 1 year high of $22.75. The firm has a market cap of $782.90 million, a price-to-earnings ratio of -24.09 and a beta of 1.27.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings data on Monday, May 14th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.19) by $0.01. Abeona Therapeutics had a negative net margin of 939.83% and a negative return on equity of 23.57%. The company had revenue of $2.60 million for the quarter, compared to the consensus estimate of $0.27 million. equities analysts anticipate that Abeona Therapeutics will post -0.7 earnings per share for the current fiscal year.

Large investors have recently modified their holdings of the company. Knott David M purchased a new stake in shares of Abeona Therapeutics in the first quarter valued at about $101,000. Virginia Retirement Systems ET AL acquired a new stake in shares of Abeona Therapeutics in the first quarter valued at about $152,000. Teacher Retirement System of Texas acquired a new stake in shares of Abeona Therapeutics in the fourth quarter valued at about $163,000. Sabby Management LLC acquired a new stake in shares of Abeona Therapeutics in the first quarter valued at about $187,000. Finally, MetLife Investment Advisors LLC acquired a new stake in shares of Abeona Therapeutics in the fourth quarter valued at about $194,000. 69.11% of the stock is currently owned by institutional investors and hedge funds.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply